Sign in

    Abbott Laboratories (ABT)

    Q4 2023 Earnings Summary

    Reported on Jan 10, 2025 (Before Market Open)
    Pre-Earnings Price$114.00Last close (Jan 23, 2024)
    Post-Earnings Price$110.75Open (Jan 24, 2024)
    Price Change
    $-3.25(-2.85%)

    What went well

    • Abbott forecasts 8% to 10% organic sales growth for 2024, driven by a strong core business and strategic reinvestment from COVID-19 revenue into its base business, resulting in all four major segments being in better and stronger shape than pre-pandemic.
    • The company expects margin expansion, particularly in gross margin, with a forecasted increase of approximately 75 basis points in 2024, providing a significant opportunity to drive earnings growth over the next couple of years.
    • Abbott's robust pipeline, including its "Fab 5" new products, is expected to grow 50% and contribute about 1 point of growth to the overall company in 2024, supporting sustainable top-tier growth beyond 2024 and 2025.

    What went wrong

    • Potential discrepancies in FreeStyle Libre sales data could indicate overstated growth. Investors have observed that IQVIA prescription data shows flattening prescriptions for Libre, yet Abbott reports continued sales growth, suggesting possible discrepancies in reported figures.
    • Upcoming competitive launches may pressure Abbott's Electrophysiology business. With new Pulsed Field Ablation (PFA) technologies entering the U.S. market, Abbott acknowledges potential uptake by competitors, which could impact their market share in this segment.
    • Macroeconomic and geopolitical volatility could affect growth projections. Abbott's confidence in their earnings range considers potential volatility, but unforeseen global events could negatively impact performance.

    Q&A Summary

    1. Increased Organic Growth Guidance
      Q: What's driving confidence in higher 8%-10% organic growth guidance?
      A: Abbott is confident in guiding higher organic growth due to reinvesting COVID revenues into strengthening their four business segments, making them stronger than pre-pandemic levels. Each segment—EPD, Nutrition, Diagnostics, and Medical Devices—has improved performance, with notable double-digit growth and margin expansion. The core business grew EPS over 40% last year, and they forecast double-digit EPS growth this year, capturing opportunities despite global volatility.

    2. Margin Expansion Outlook
      Q: What's the outlook for margin expansion and its drivers?
      A: Abbott aims to expand gross margins by approximately 75 basis points this year, primarily through internal improvement programs, cost tailwinds (commodities, freight), and favorable portfolio mix with higher-margin Device businesses growing faster. They expect to return to pre-pandemic gross margin profiles over time, driving earnings growth in the coming years.

    3. FreeStyle Libre Growth Prospects
      Q: Where will Libre's growth come from, and why the data discrepancy?
      A: Libre's growth will come from the basal insulin segment, a significant multi-year opportunity, and from pump connectivity now that they have regulatory clearings. In Q4, U.S. growth was 32%, even without fully launching Libre 3. The discrepancy with IQVIA data is because IQVIA doesn't capture the entire market; segments beyond the pharmacy channel drive additional adoption.

    4. Pipeline and 'Fab 5' Products Update
      Q: What's the update on the 'Fab 5' products and their impact on growth?
      A: The 'Fab 5' products remain significant growth drivers, contributing about 1 point to Abbott's total growth in 2024, with expected growth of 50%. They include both market-creating (e.g., tricuspid valve repair, CardioMEMS) and market-conversion products (e.g., Navitor in TAVR, Aveir in CRM). Beyond the 'Fab 5', Abbott has a robust pipeline, including Lingo, traumatic brain injury tests, and new Alinity systems, to sustain growth beyond 2024.

    5. M&A Strategy and Appetite
      Q: What's Abbott's appetite for larger M&A transactions?
      A: With a strong balance sheet and over $20 billion in firepower, Abbott is selective about M&A. They have a robust pipeline and don't need acquisitions to cover top-line gaps. They focus on strategic fit and attractive returns, emphasizing profitability and earnings over mere revenue growth, recognizing that larger deals are harder to justify but remain open to opportunities.

    6. Medical Device Market Trends
      Q: Is higher procedure utilization boosting growth or is it normalized?
      A: Abbott sees procedures returning to normal levels without pent-up demand driving growth. Growth is driven by increased adoption of new technologies and return to normal procedure cadence across segments like structural heart, CRM, EP, and routine diagnostics.

    7. Electrophysiology Business Growth
      Q: How is EP achieving strong growth despite competition?
      A: EP growth is strong globally due to a robust portfolio, including the EnSite X mapping system and TactiFlex catheter, delivering excellent results. A dedicated team close to customers has helped sustain growth even with new competitive products entering the market. Abbott expects continued growth, acknowledging PFA systems' emergence but is confident in their offerings.

    8. Nutrition Segment Growth Outlook
      Q: Is Nutrition back on track, and what is the growth outlook?
      A: Abbott's Nutrition segment has regained market leadership and expects to surpass pre-recall share levels. The segment is expected to grow above the pre-pandemic 4%-6% range in 2024 due to regained share and pricing impacts. Adult Nutrition is highlighted as a significant growth driver, growing at high-single digits, potentially exceeding the higher end of the 6% range with new product launches.

    Related Publications